Immunocore (IMCR) Stock Price, News & Analysis

+1.49 (+2.67%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
302,166 shs
Average Volume
484,334 shs
Market Capitalization
$2.86 billion
P/E Ratio
Dividend Yield
Price Target

Immunocore MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
41.8% Upside
$81.50 Price Target
Short Interest
9.49% of Float Sold Short
Dividend Strength
News Sentiment
1.73mentions of Immunocore in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.54) to ($1.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.44 out of 5 stars

Medical Sector

519th out of 910 stocks

Biological Products, Except Diagnostic Industry

80th out of 153 stocks

IMCR stock logo

About Immunocore Stock (NASDAQ:IMCR)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

IMCR Stock Price History

IMCR Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
IMCR Apr 2024 45.000 put
IMCR Apr 2024 95.000 call
Immunocore presented two posters at CROI 2024
Key Takeaways From Immunocore Hldgs Analyst Ratings
Immunocore FY 2023 Earnings Preview
Immunocore Holdings Ltd (IMCR)
See More Headlines
Receive IMCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
13 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$249.43 million
Book Value
$7.42 per share


Free Float
Market Cap
$2.86 billion
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Bahija Jallal Ph.D. (Age 63)
    CEO & Director
    Comp: $1.42M
  • Mr. Brian R. Di Donato M.B.A. (Age 57)
    CFO & Head of Strategy
  • Mr. John Trainer M.B.A. (Age 50)
    SVP & Chief Operating Officer
  • Mr. John Goll III
    SVP, Finance & Chief Accounting Officer
  • Ms. Annelise Vuidepot Ph.D.
    CTO and Head of Pipeline & Platform Research
  • Mr. Sean D. Buckley (Age 41)
    VP & Chief Information Officer
  • Clayton Robertson
    Head of Investor Relations
  • Ms. Lily Margaret Hepworth
    General Counsel & Company Secretary
  • Ms. Elizabeth Varki Jobes Esq. (Age 57)
    J.D., Chief Compliance Officer
  • Mr. Sébastien Desprez
    Head of Communications

IMCR Stock Analysis - Frequently Asked Questions

Should I buy or sell Immunocore stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IMCR shares.
View IMCR analyst ratings
or view top-rated stocks.

What is Immunocore's stock price target for 2024?

13 brokerages have issued 1 year target prices for Immunocore's stock. Their IMCR share price targets range from $63.00 to $92.00. On average, they anticipate the company's share price to reach $81.50 in the next twelve months. This suggests a possible upside of 41.8% from the stock's current price.
View analysts price targets for IMCR
or view top-rated stocks among Wall Street analysts.

How have IMCR shares performed in 2024?

Immunocore's stock was trading at $68.32 at the beginning of 2024. Since then, IMCR stock has decreased by 15.9% and is now trading at $57.49.
View the best growth stocks for 2024 here

Are investors shorting Immunocore?

Immunocore saw a increase in short interest in March. As of March 31st, there was short interest totaling 4,610,000 shares, an increase of 7.5% from the March 15th total of 4,290,000 shares. Based on an average trading volume of 491,700 shares, the short-interest ratio is currently 9.4 days. Currently, 9.5% of the shares of the stock are short sold.
View Immunocore's Short Interest

When is Immunocore's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our IMCR earnings forecast

How were Immunocore's earnings last quarter?

Immunocore Holdings plc (NASDAQ:IMCR) posted its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.12. The business had revenue of $70.16 million for the quarter, compared to analysts' expectations of $53.25 million. Immunocore had a negative trailing twelve-month return on equity of 15.78% and a negative net margin of 22.48%. The business's quarterly revenue was up 22.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.63) EPS.

When did Immunocore IPO?

Immunocore (IMCR) raised $199 million in an initial public offering on Friday, February 5th 2021. The company issued 8,300,000 shares at a price of $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies served as the underwriters for the IPO.

Who are Immunocore's major shareholders?

Immunocore's stock is owned by a variety of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.18%) and Hennion & Walsh Asset Management Inc. (0.04%).
View institutional ownership trends

How do I buy shares of Immunocore?

Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMCR) was last updated on 4/23/2024 by Staff

From Our Partners